Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.47 |
| ▸ | PDE8B | O95263 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537437 | 0.71 | ADORA2A (0.54) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL536705 | 0.66 | ADORA2A (0.57) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL4046969 | 0.64 | ADORA2A (1.00) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL536715 | 0.64 | ADORA2A (0.57) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL536678 | 0.62 | ADORA2A (0.55) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL536739 | 0.62 | ADORA2A (0.63) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL20677879 | 0.62 | ADORA2A (0.61) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL536604 | 0.61 | ADORA2A (0.74) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL4044294 | 0.60 | ADORA2A (0.65) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL536807 | 0.59 | ADORA2A (0.61) | ADORA3ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10106547-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2018-10-23 | — | — | US | disclosed |
| US-20170342081-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106547-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | ADORA3 14/4885ADORA2A 11/4885ADORA2B 19/4885 |
| US-20170342081-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | ADORA3 14/4885ADORA2A 11/4885ADORA2B 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.